Actuate Therapeutics Inc
NASDAQ:ACTUBiotechnology
+$0.06 today
- Market cap
- $50.01M
- Beta
- 0.53
- P/E (TTM)
- -2.3
- EPS (TTM)
- -$0.92
Volume 0.03M
Average 0.16M
ACTU Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
Actuate Therapeutics IncNASDAQ: ACTU
Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other current liabilities rises 184.4% from a year ago
Other current liabilities stood at $3.52M at the end of Q1 FY2026, up 184.4% from a year earlier and down 2.1% from the prior quarter. Over 3 fiscal years it compounded at +20.0% a year.
Context
- Other current liabilities amounted to 39.5% of total assets at the end of Q1 FY2026, up 11.9 pp from a year earlier.
- Other current liabilities increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other current liabilities keeps rising in the next quarterly balance sheet after a +184.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $3.52M-2.1% QoQ
- Last fiscal yearDec 2025
- $3.59M+395425962596259520.0% YoY
- Year agoMar 2025
- $1.24M+184.4% since
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 3.59M USD
- Year-over-year change
- +395425962596259520.0%
- 3-year CAGR
- +20.0%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.59M | +395425962596259520.0% |
| FY2024 | 2024-12-31 | 0 | -100.0% |
| FY2023 | 2023-12-31 | 277.5K | -86.7% |
| FY2022 | 2022-12-31 | 2.08M | — |
Other Current Liabilities vs competitors
How ACTU compares with its peers on the latest reported figures
- Peers report in different currencies, so other current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +184.4% is the 2nd highest of 8, against a peer median of -25.2%.
- Other current liabilities amounts to 39.5% of total assets for ACTU, versus a peer median of 0.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
ELTXElicio Therapeutics, Inc. | Mar 2026 | $5.92M USD | +329.2% | +78.6% | 26.1% |
| Mar 2026 | $4.3M USD | +63.4% | -49.2% | 3.7% | |
ACTUActuate Therapeutics Inc | Mar 2026 | $3.52M USD | +184.4% | +20.0% | 39.5% |
| Mar 2026 | $2.98M USD | -51.3% | -13.4% | 0.8% | |
| Mar 2026 | $2.92M USD | +36.3% | +45.8% | 0.6% | |
| Mar 2026 | $1.43M USD | -25.2% | +24.1% | 0.9% | |
| Mar 2026 | $0 USD | -100.0% | +24.1% | 0.0% | |
| Mar 2026 | $0 USD | -100.0% | -7.4% | 0.0% | |
| Mar 2026 | -CHF 20.53K CHF | — | — | 0.0% | |
| Peer median (excluding ACTU) | — | -25.2% | +24.1% | 0.7% | |
Competitors are the stored peer set for ACTU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Actuate Therapeutics Inc
NASDAQ:ACTU
Intrinsic Alpha fair value
Locked
Current Price
$2.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.